Moreover, PSMA-PET is used in advanced stages of castration resistant prostate cancer to assess PSMA expression as a prerequisite for eligibility of radioligand therapy or to monitor the disease burden and decide on treatment intensification [4–7]. Here, FOLH1 is linked to prostate cancer.